1) Strong Q1 Performance and Guidance Update - Centene reported Q1 2026 adjusted diluted EPS of $3.37, exceeding expectations and prompting an increase in full-year adjusted EPS guidance to greater than $3.40 from greater than $3.00. - Total premium and service revenue reached $44.7 billion for the quarter. - The company emphasized operational improvements and increased visibility contributing to positive financial momentum.

2) Segment Results: Medicaid, Medicare, and Marketplace - Medicaid: - Membership stood at 12.4 million, with a Q1 HBR of 93.1%, up 50 basis points YoY. - Performance was bolstered by a lighter flu season and favorable weather, alongside effective trend management initiatives. - Medicare: - Both Medicare Advantage and PDP exceeded expectations, with an HBR of 84.9%. - Membership in PDP reached 8.7 million, benefiting from lower specialty drug trends. - Marketplace: - Membership was approximately 3.6 million, with a slightly higher-than-expected HBR due to increased utilization in the Silver tier, offset by strong SG&A management.

3) Operational Improvements and Strategic Initiatives - Centene is focused on modernizing and standardizing processes across its Medicaid business to manage medical cost trends effectively. - The company is enhancing its value-based care strategy, particularly in high-cost specialties like oncology and behavioral health. - Leadership changes were announced, with Dan Finke and Michael Carson taking on Group President roles to strengthen performance across Medicaid and Medicare segments.

4) Challenges and Market Dynamics - The company noted pockets of deceleration in trend management, particularly in behavioral health, but remains optimistic about ongoing improvements. - The expiration of enhanced APTCs has led to a shift in membership dynamics, particularly within the Marketplace, with higher acuity members remaining in the Silver tier. - Centene is actively engaging with state partners to align program revenue with member acuity, particularly in light of upcoming work requirements.

5) Outlook and Investor Considerations - Centene anticipates a composite rate yield of approximately 4.5% for Medicaid, with ongoing constructive conversations with state departments. - The company is cautious about the remainder of 2026, embedding a prudent margin forecast in its guidance while awaiting further data to refine risk adjustment assumptions. - The Q1 earnings call did not provide detailed projections for Q2-Q4 margins, leaving some uncertainty for investors regarding the quarterly progression.

Bottom line: Centene's strong Q1 results and increased guidance reflect operational improvements and strategic focus across its segments, but challenges in trend management and market dynamics warrant a cautious outlook for the remainder of 2026. Investors should monitor the evolving risk adjustment landscape and state partnerships as key factors influencing future performance.